Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India

• Published in: South Asian Journal of Cancer 2017-01, Vol.6 (1), p.020-024
• Main Authors: Talwar, Vineet, Nirni, Sharanabasappa S., Mallavarapu, Krishna Mohan, Ramkumar, Anupama, Sinha, Nitu
• Format: Article
• Language: English
• Subjects: Chemotherapy-induced neutropenia; febrile neutropenia; granulocyte colony-stimulating factor; myelosuppressive chemotherapy; ORIGINAL ARTICLE: Supportive Care; Peg-grafeel; pegfilgrastim; postmarketing surveillance study
• ISSN: 2278-330X; 2278-4306
• DOI: 10.4103/2278-330X.202560

Abstract Background: A granulocyte colony-stimulating factor, pegfilgrastim, is efficacious though expensive for prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia. Biologics available and accessible today, having acceptable safety-efficacy profiles, require postapproval studies for better understanding of such drugs in clinical settings. Aim: This postmarketing surveillance study evaluated the safety of prophylactic Peg-grafeel ™ (pegfilgrastim) in cancer patients with chemotherapy-induced neutropenia. Settings and Design: This prospective, noninterventional, single-arm, open-label study was conducted at 10 study sites in India. Methods: Patients received subcutaneous 6 mg Peg-grafeel ™ approximately 24 h following chemotherapy as part of routine patient care. Statistical Analysis: Data were summarized descriptively. Results: The study included 250 patients (male: female = 36.4%:63.6%; median age, 54 [16–80] years). Most patients had Stage III (33.2%) or IV (41.6%) cancers and received cyclophosphamide (37.2%) and doxorubicin (31.6%) as chemotherapy. On an average, 4 Peg-grafeel ™ doses were administered per patient. Treatment-emergent adverse events (AEs) were reported in 115 (46%) patients, the most common being vomiting (11.6%), pain (11.2%), nausea (8.4%), and constipation (8.4%). Peg-grafeel ™ -related AEs included pain (3.2%), asthenia (2.4%), and arthralgia (1.2%). Bone pain (0.4%) and extremity pain (1.2%) were rare. Grade 3/4 neutropenia and febrile neutropenia occurred in 4 (1.6%) and 3 (1.2%) patients, respectively. Serious AEs included vomiting (2.8%) and pyrexia (2%). No new safety concerns were identified. None of the five deaths was considered related to Peg-grafeel ™ . Conclusion: The overall safety profile of Peg-grafeel ™ was consistent with the expected safety profile of pegfilgrastim in patients with advanced malignancies in a clinical setting.